Clinical Trials Browser

Papillomavirus Infections × Papillomavirus Vaccines × Gynecologic × Clear all

Acquired Immunodeficiency Syndrome, Uterine Cervical Dysplasia, Papillomavirus Infections

NCT06700941 2024-11-22

Impact of HPV Vaccination Against Cervical Lesions and Genital Warts in Colombia. an Ecological Assessment

Completed

8,000,000 enrolled

Gynecologic

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Condylomata Acuminata, Papillomavirus Infections

NCT06686043 2024-11-13

HPV-VIM

Phase 2 Recruiting

85 enrolled

Gynecologic

Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Papillomavirus Infections

NCT03900572 2023-04-13

A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine

Phase 1 Completed

90 enrolled

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Papillomavirus Infections

NCT05694728 2023-01-23

A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine

Phase 2 Completed

780 enrolled

GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vulvar Neoplasms, Papillomavirus Infections

NCT05680454 2023-01-17

A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine

Phase 1 Completed

160 enrolled

GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT05662020 2022-12-27

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Phase 3 Active not recruiting

2,750 enrolled

GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT04171505 2019-11-21

VENUS

Unknown

508 enrolled

Gynecologic

Uterine Cervical Dysplasia, Papillomavirus Infections

NCT00541970 2018-08-17

Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs

Phase 1 Completed

961 enrolled 43 charts

Gynecologic

Uterine Cervical Neoplasms, Virus Diseases, Papillomavirus Infections

NCT00578227 2018-08-17

Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects

Phase 3 Completed

814 enrolled 28 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00652938 2018-08-17

Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects

Phase 3 Completed

744 enrolled 27 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00552279 2018-06-25

Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age

Phase 3 Completed

805 enrolled 16 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

Clinical Trials

AGO-Gard

Impact of HPV Vaccination Against Cervical Lesions and Genital Warts in Colombia. an Ecological Assessment

HPV-VIM

A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine

A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine

A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

VENUS

Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs

Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects

Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects

Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age